<DOC>
	<DOCNO>NCT01203826</DOCNO>
	<brief_summary>This clinical trial study long term safety efficacy asfotase alfa child HPP complete ENB-006-09 study .</brief_summary>
	<brief_title>Extension Study Protocol ENB-006-09 - Study Asfotase Alfa Children With Hypophosphatasia ( HPP )</brief_title>
	<detailed_description>Asfotase alfa formerly refer ENB-0040 Hypophosphatasia ( HPP ) life-threatening , genetic , ultra-rare metabolic disease characterize defective bone mineralization impair phosphate calcium regulation lead progressive damage multiple vital organ , include destruction deformity bone , profound muscle weakness , seizure , impair renal function , respiratory failure . There approve disease-modifying treatment patient disease . There also limit data available natural course disease time , particularly patient juvenile-onset form .</detailed_description>
	<mesh_term>Hypophosphatasia</mesh_term>
	<criteria>Compliant satisfactory completion Enobiasponsored clinical trial ENB00609 Written inform consent parent legal guardian prior study procedure perform Parent legal guardian willing comply study requirement Clinically significant disease precludes study participation , Investigator 's opinion Treatment investigational drug Asfotase Alfa Enrollment study involve investigational drug , device , treatment HPP</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hypophosphatasia</keyword>
	<keyword>HPP</keyword>
	<keyword>Bone Disease</keyword>
	<keyword>Soft Bones</keyword>
	<keyword>Low Alkaline Phosphatase</keyword>
	<keyword>genetic metabolic disorder</keyword>
	<keyword>alkaline phosphatase</keyword>
	<keyword>tissue non-specific alkaline phosphatase</keyword>
	<keyword>rickets</keyword>
	<keyword>osteomalacia</keyword>
</DOC>